Selection of the Best Blood Compartment to Measure Cytidine Deaminase Activity to Stratify for Optimal Gemcitabine or Cytarabine Treatment
- 4 April 2014
- journal article
- other
- Published by Taylor & Francis in Nucleosides, Nucleotides and Nucleic Acids
- Vol. 33 (4-6), 403-412
- https://doi.org/10.1080/15257770.2014.894196
Abstract
Cytidine deaminase (CDA) plays a crucial role in the degradation of cytidine analogs, such as gemcitabine and cytarabine. Several studies showed that a low CDA activity is associated with more toxicity but a higher efficacy, while a high activity will lead to a lower efficacy but less toxicity. A stratified dosing strategy based on the relative CDA activity would increase efficiency. In order to predict these events, a reliable measurement of CDA with a validated method is crucial. We aimed to determine which phenotype assay would be most suitable; a spectrophotometric assay using cytidine as a substrate, or an HPLC assay using gemcitabine as a substrate. In serum and whole blood of 26 volunteers, both assays showed an excellent correlation (R > 0.999), but not in plasma nor in red blood cells. Moreover, there was no difference between males and females. In conclusion, the spectrophotometric assay seems the most simple and cost-effective test. It should be performed in serum, while it should be normalized on protein content as measured by the Bicinchoninic Acid.Keywords
This publication has 23 references indexed in Scilit:
- Gender, Cytidine Deaminase, and 5-Aza/Decitabine—LetterClinical Cancer Research, 2013
- Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patientsAnnals of Oncology, 2011
- Integrating pharmacogenetics into gemcitabine dosing—time for a change?Nature Reviews Clinical Oncology, 2011
- Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulationPharmacogenetics and Genomics, 2007
- Pharmacokinetics of Gemcitabine in Japanese Cancer Patients: The Impact of a Cytidine Deaminase PolymorphismJournal of Clinical Oncology, 2007
- Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus CisplatinClinical Cancer Research, 2005
- Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathwayThe Pharmacogenomics Journal, 2004
- Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)Drug Resistance Updates, 2002
- Serum cytidine deaminase as a laboratory test for acute inflammation in rheumatoid arthritis.Annals Of The Rheumatic Diseases, 1988
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976